Navigation Links
Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
Date:5/28/2013

BURLINGTON, Mass., May 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that expanded labeling for additional neuropathic pain (NP) populations and/or broader NP labeling (peripheral NP) will not ensure increased physician prescribing or improved formulary coverage. Instead, survey findings reveal that primary care physicians, pain specialists and neurologists are comfortable prescribing NP therapies to an array of NP populations for which the agents are not specifically labeled, and the majority of surveyed managed care organization (MCO) directors will reimburse these therapies for any form of NP, at the physician's discretion.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

"Most surveyed payers recognize the difficulty in treating NP and agree that reimbursement for NP will be less restrictive than reimbursement for other forms of chronic pain," said Decision Resources Principal Business Insights Analyst Andrea Buurma . "However, newer agents like Depomed's Gralise and XenoPort's Horizant face more restrictive coverage on surveyed payers' commercial plans and Medicare prescription drug plans, likely because these agents' parent molecule, gabapentin, is available generically and has widespread, favorable formulary coverage."

The U.S. Physician & Payer Forum report entitled Neuropathic Pain: U.S. Payer and Prescriber Attitudes Toward Recently Approved and Emerging Therapies—Implications for Market Access finds that safety and/or tolerability advantages could positively influence formulary decisions owing to subsequent improvements in patient quality of life, thus offsetting downstream healthcare costs. However, emerging therapies that are reformulations of already-available molecules—and offer limited advantages beyond improved delivery—will likely face significant market access hurdles, particularly if priced at a premium to their parent molecules. Indeed, MCOs have largely excluded, unfavorably tiered, or attached prior authorization and/or step therapy protocols to Gralise and Horizant, gabapentin reformulations that offer less frequent dosing than generic gabapentin.

The findings also reveal that the ability of Janssen's Nucynta ER to reduce pain intensity is the primary factor driving its use for NP among surveyed physicians who currently prescribe or plan to prescribe the drug. Furthermore, although Nucynta ER is approved for only one NP indication—painful diabetic neuropathy—many surveyed physicians report that they prescribe or will prescribe the drug to patients with other forms of NP, such as neuropathic back pain. However, Nucynta ER is and will be largely reserved as a second-line or later therapy, likely resulting from its Schedule II status; the entrenchment of early-line therapies such as gabapentin, Pfizer's Lyrica and Eli Lilly's Cymbalta; and step therapy and prior authorization requirements instituted by surveyed MCO directors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
2. Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA
3. Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
4. PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
5. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
6. Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules
7. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
8. ThermoGenesis Announces Axp Approval In Thailand
9. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
10. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
11. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... patient has been enrolled in a Phase 3 clinical ... best supportive care (BSC) in the prevention of hepatic ... hematopoietic stem cell transplant (HSCT) who are at high ... The defibrotide clinical trial will be conducted across approximately ...
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a ... Devices Market is expected to reach USD 33.6 million during the ... Market Highlights ... The Global Endoscopy Devices Market has been examined as a swiftly ... there is huge demand for endoscopy device in various regions.  The ...
(Date:1/17/2017)... 17, 2017 Following an initial analysis, ... the Food and Drug Administration,s (FDA,s) final regulatory ... Products by Pharmacies and Outsourcing Facilities." In its ... on pre-packaging -- which would have put patients ... long term care (LTC) pharmacies.  ...
Breaking Medicine Technology:
(Date:1/17/2017)... Utah (PRWEB) , ... January 17, 2017 , ... ... of accredited, online continuing education for EMS and firefighting professionals, has released four ... (VILT) Solution. These new courses are taught live in an online classroom and ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides asset ... charity drive to raise awareness of heart disease and promote habits that improve heart ... responsible for 1 in every 4 deaths at the national level each year. In ...
(Date:1/17/2017)... NJ (PRWEB) , ... January 17, 2017 , ... ... personality, and breast cancer survivor Sandra Lee as keynote speaker for the 34th ... Beach, Florida. , In making the announcement, PER® president, Phil Talamo, said, “We ...
(Date:1/17/2017)... NJ (PRWEB) , ... January 17, 2017 , ... ... Learning Center and the Montclair State University’s Athletic Training Education program forged a ... University’s Athletic Training Education Program, which is consists of both student members ...
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic ... groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show on January ... #2809. The SHOT Show is the shooting, hunting and outdoor trade show and ...
Breaking Medicine News(10 mins):